Neuropace, Inc. - Common Stock — Filings & Documents (NASDAQ:NPCE) — Page 4 | MetaTrader

Open full chart

Financials

Overview Statement Statistics Documents

2024

Current report, Q3 FY2024

Neuropace Inc current report, Q3 FY2024

Quarterly report, Q2 FY2024

Neuropace Inc quarterly report, Q2 FY2024

1
2
3
4

News

NeuroPace Faces an IGE Delay: What the FDA Setback Means for Growth

Is NeuroPace a Buy as Growth Improves but Valuation Stays Elevated?

NPCE Is Down 12.7% in 3 Months: Is the Pullback a Buying Opportunity?

NeuroPace, Inc. (NPCE) Q2 2026 Earnings Call Transcript

NPCE Q2 Earnings Beat Estimates on RNS Growth, '26 Revenue View Up

NeuroPace, Inc. (NPCE) Reports Q2 Loss, Tops Revenue Estimates

CVRx (CVRX) Reports Q2 Loss, Beats Revenue Estimates

NeuroPace, Inc. (NPCE) Discusses FDA Feedback on PMA Supplement for Indication Expansion into Idiopathic Generalized Epilepsy Transcript

Here's Why You Should Retain NeuroPace Stock in Your Portfolio for Now

Wall Street Analysts Believe NeuroPace (NPCE) Could Rally 27.88%: Here's is How to Trade

NeuroPace (NPCE) Down 0.6% Since Last Earnings Report: Can It Rebound?

Here's Why You Should Add NeuroPace Stock to Your Portfolio Now